CagriSema / CagriTriz / CagriReta (Cagrilintide + GLP-1 Agonist)

Amylin and GLP-1 are two independent gut-brain satiety signals, and pairing them is one of the most mechanistically compelling weight-loss combinations currently under active development. Cagrilintide is a long-acting amylin analog designed for once-weekly subcutaneous dosing, engineered from native human amylin with a lipid side chain that extends its half-life to about 7 days. Native amylin and its short-acting analog pramlintide are released with insulin from pancreatic beta cells and slow gastric emptying, suppress postprandial glucagon, and enhance satiety via central amylin and calcitonin receptors. Cagrilintide provides that signal continuously, not just around meals. GLP-1 receptor agonists — semaglutide (pure GLP-1), tirzepatide (GLP-1 + GIP dual), and retatrutide (GLP-1 + GIP + glucagon triple) — drive weight loss primarily through central anorectic signaling, slowed gastric emptying, and insulin sensitization. The mechanisms overlap partially (both slow gastric emptying) but are largely additive: amylin agonism at calcitonin/amylin receptors is pharmacologically distinct from GLP-1 receptor agonism, and the two pathways converge on different central appetite circuits. The clinical hope is that stacking them extends the weight-loss ceiling beyond what either class achieves alone. The three variants differ only in the GLP-1 backbone. CagriSema is Novo Nordisk's formally developed co-administration of cagrilintide and semaglutide. CagriTriz — cagrilintide plus tirzepatide — is not a formal product (cagrilintide is Novo, tirzepatide is Lilly, and the two companies are direct competitors) and exists only as an off-label compounded or investigator-stacked combination. CagriReta — cagrilintide plus retatrutide — is similarly conceptual, with retatrutide not yet fully approved and no announced development program pairing it with an amylin analog. Most readers encountering these names are interested in CagriSema clinically and in the other two as theoretical maximalist stacks.

Cagrilintide binds both the amylin receptor (AMY, a heteromer of the calcitonin receptor with receptor activity-modifying proteins 1 and 3) and the calcitonin receptor itself. Activation slows gastric emptying, suppresses postprandial glucagon secretion, and reduces food intake through signaling to the area postrema and subsequent central anorectic circuits. Continuous weekly exposure provides tonic amylin-receptor engagement rather than the meal-linked pulses that native amylin supplies. The GLP-1 partner activates the GLP-1 receptor on pancreatic beta cells (enhancing glucose-dependent insulin secretion), on gastric smooth muscle (slowing emptying), and — critically for weight loss — on hypothalamic, brainstem, and vagal afferent neurons that integrate into central appetite control. Tirzepatide adds GIP receptor agonism, which further enhances insulin secretion and appears to contribute additional central anorectic signal; retatrutide adds glucagon receptor agonism on top, which raises resting energy expenditure and liver fat oxidation. The stacked effect is not simply additive arithmetic. Amylin and GLP-1 act on distinct central circuits and produce complementary profiles of satiety, delayed gastric emptying, and glucagon suppression. In the REDEFINE-1 trial, the full-dose cagrilintide 2.4 mg plus semaglutide 2.4 mg combination produced roughly 22.7% mean weight loss at 68 weeks versus about 15-16% with semaglutide alone — a meaningful incremental gain beyond either monotherapy. The pharmacologic rationale is that you are layering two independent gut-brain satiety axes rather than escalating a single axis.

CagriSema is the only variant with pivotal clinical evidence. Novo Nordisk's REDEFINE program — REDEFINE 1 in obesity without diabetes (2024/2025 readout), REDEFINE 2 in obesity with type 2 diabetes, and REDEFINE 3 in cardiovascular outcomes — has generated the definitive data set. REDEFINE 1 reported approximately 20-23% mean body weight reduction at 68 weeks in the modified intention-to-treat analysis, with a notable tail of patients reaching 25-30% loss. The cardiovascular outcome data are maturing. Early regulatory filings began in 2025, with approvals expected in 2026 in major markets. CagriTriz has no published clinical trial data as a formal product because cagrilintide (Novo) and tirzepatide (Lilly) are developed by competing companies. Any real-world use is through compounded pharmacies or off-label patient-initiated stacking, with no controlled efficacy or safety data specific to the combination. The mechanistic rationale is strong, but the evidence is absent. CagriReta is the most speculative of the three. Retatrutide itself completed Phase 3 development in 2025 and was filed for approval in late 2025/early 2026, but no announced development program combines it with cagrilintide. Any CagriReta combination would be theoretical until a formal program emerges or a compounding pharmacy produces one. The upside — amylin plus triple-agonist incretin — is pharmacologically dramatic on paper, but there is no efficacy or safety data to support it in humans.

CagriSema in the REDEFINE program is delivered as two separate weekly subcutaneous injections: cagrilintide (escalated from 0.25 mg to 2.4 mg weekly over roughly 16 weeks) and semaglutide (escalated from 0.25 mg to 2.4 mg weekly on the standard Wegovy schedule). Both are titrated in parallel, with injections given on the same day but from separate pens. A fixed-dose combination pen is under commercial development. Full-dose maintenance is cagrilintide 2.4 mg + semaglutide 2.4 mg once weekly. CagriTriz and CagriReta, where they exist, would pair cagrilintide (typically at the approved CagriSema dose) with tirzepatide (standard weekly titration to 10-15 mg maintenance) or retatrutide (whatever maintenance dose emerges from the Phase 3 program, expected in the 6-12 mg weekly range). These combinations are not developed products and have no established titration protocol; any real-world use is off-label and should be overseen by a clinician familiar with both components. All three combinations should be managed by a qualified clinician with baseline and periodic monitoring of weight, glycemia, and gastrointestinal tolerability. Dose escalation in parallel amplifies gastrointestinal side effects, particularly nausea and vomiting, and many protocols stagger or slow the titration on one component to improve tolerability.